Abstract

Review Article

Pseudoephedrine protects mice from infection of H1N1 virus

Zhongping Wu*, Li Deng, Chengzhi Chu and Xiaoyin Chen*

Published: 28 February, 2020 | Volume 4 - Issue 1 | Pages: 014-020

Ephedra, an ancient herb, is applied to treat common cold and influenza for such a long time in China. Pseudoephedrine is a main active ingredient from Ephedra which is used for relieving nasal congestion clinically. We previously reported that pseudoephedrine showed a potent anti-inflammatory effect other than sympathomimetic effects. In the present study, we aimed to investigate whether pseudoephedrine could protect mice from the H1N1 virus infection. The mice were infected with a 20% LD50 influenza A virus (IAV) suspension via intranasal administration to establish a virus infection model. Further, the mice were orally administered pseudoephedrine or oseltamivir for 4 days from one day after infection. Our results showed that pseudoephedrine improved lung pathological damage during the IVA infection period, and it dramatically increased the survival rate and attenuated loss of body weight compared with the virus-infected control group. In addition, pseudoephedrine inhibited the cytokine storms and mRNAs expression of the TLR7 signaling pathway. Surprisingly, pseudoephedrine showed an inhibitory effect on the replication of IAV. These results give clear evidence that pseudoephedrine is a potential anti-influenza drug by blunting cytokine storms and inhibition of replication of IAV, and following these results, we speculate that it should be tested in the novel coronavirus pneumonia (COVID-19, a severe epidemic in China currently) in which the cytokine storms play a key role to damage bronchi and lung in the early stage.

Read Full Article HTML DOI: 10.29328/journal.ijcv.1001008 Cite this Article Read Full Article PDF

Keywords:

Pseudoephedrine; Influenza A virus; Cytokine storm; Replication of influenza a virus

References

  1. Kmietowicz Z. WHO downgrades oseltamivir on drugs list after reviewing evidence. BMJ. 2017; 357: j2841. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28607038
  2. Wang C, Cao B, Liu QQ, Zou ZQ, Liang ZA, et al. Oseltamivir compared with the Chinese raditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med. 2011; 155: 217-225. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21844547
  3. Wu Z, Kong X, Zhang T, Ye J, Fang Z, et al. Pseudoephedrine/ephedrine shows potent anti-inflammatory activity against TNF-α-mediated acute liver failure induced by lipopolysaccharide/d-galactosamine. Eur J Pharmacol. 2014; 724: 112-121. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24365491
  4. Gelotte CK, Albrecht HH, Hynson J, Gallagher V. A Multicenter, Randomized, Placebo-Controlled Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children with the Common Cold. J Clin Pharmacol. 2019; 59: 1573-1583. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31274197
  5. Marathe BM, Mostafa HH, Vogel P, Pascua PNQ, Jones JC, et al. A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment. Antiviral Res. 2017; 148: 20-31. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29100887
  6. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124: 188-195. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24876563
  7. Teijaro JR, Walsh KB, Rice S, Rosen H, Oldstone MB. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci U S A. 2014; 111: 3799-3804. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24572573
  8. Richman DD, Whitley RJ, Hayden FG. Clinical Virology. Third Edition ed. 2009.
  9. Han Y, Zhu J, Wu Z. Ephedra protects rats against acute liver failure induced by D-galactosamine and lipopolysaccharide. Zhonghua Gan Zang Bing Za Zhi. 2016; 24: 127-129. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26983481
  10. Jacobs JL, Coyne CB. Mechanisms of MAVS regulation at the mitochondrial membrane. J Mol Biol. 2013; 425: 5009-5019. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24120683
  11. Lee WS, Hsu CY, Wang PL, Huang CY, Chang CH, et al. Identification and characterization of the nuclear import and export signals of the mammalian Ste20-like protein kinase 3. FEBS Lett. 2004; 572: 0-45. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15304321
  12. Cao S, Liu X, Yu M, Li J, Jia X, et al. A nuclear export signal in the matrix protein of Influenza A virus is required for efficient virus replication. J Virol. 2012; 86: 4883-4891. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22345442
  13. Feng E, Ye D, Li J, Zhang D, Wang J, et al. Recent advances in neuraminidase inhibitor development as anti-influenza drugs. Chem Med Chem. 2012; 7: 1527-1536. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22807317
  14. Dickerson J, Perrier D, Mayersohn M, Bressler R. Dose tolerance and pharmacokinetic studies of L (+) pseudoephedrine capsules in man. Eur J Clin Pharmacol. 1978; 14: 253-259. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/729619
  15. Rang H, Henderson G, Flower R, Ritter J. Rang & Dale's Pharmacology. Elsevier Health Sciences. 2007.
  16. Tetro JA. Is COVID-19 Receiving ADE from Other Coronaviruses? Microbes Infect. 2020.

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More